• Takeda posted IFRS revenue of JPY 1.22 trillion for the three months ended June 30, 2026, up 10.2% from a year earlier.
• Operating profit rose 9.1% to JPY 201.42 billion, while profit attributable to owners fell 8.9% to JPY 113.2 billion.
• Basic earnings per share declined to JPY 71.65 from a year earlier; income tax expenses climbed 87.7% to JPY 49.46 billion.
• The revenue increase was primarily driven by foreign-exchange impacts from yen depreciation; restructuring expenses lifted other operating expenses by 96.8% to JPY 55.23 billion.
• Takeda maintained its full-year IFRS forecast, including revenue of JPY 4.64 trillion and operating profit of JPY 420 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Takeda Pharmaceutical Co. Ltd. published the original content used to generate this news brief on July 29, 2026, and is solely responsible for the information contained therein.